About PolyPeptide
PolyPeptide is a company based in Baar (Switzerland) founded in 1952. The company has 1,360 employees as of December 31, 2024. PolyPeptide offers products and services including Custom Research Grade Peptides, Radiolabeled Peptide, Generic Peptides, and Oligos. PolyPeptide operates in a competitive market with competitors including Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and Aperiam Bio, among others.
- Headquarter Baar, Switzerland
- Employees 1360 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Polypeptide Group Ag
-
Annual Revenue
$354.13 M (USD)3.08as on Dec 31, 2024
-
Net Profit
-$20.57 M (USD)62.71as on Dec 31, 2024
-
EBITDA
$24.57 M (USD)0as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
1360
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of PolyPeptide
PolyPeptide is a publicly listed company on the SIX with ticker symbol PPGN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of PolyPeptide
PolyPeptide offers a comprehensive portfolio of products and services, including Custom Research Grade Peptides, Radiolabeled Peptide, Generic Peptides, and Oligos.
Services for custom peptide research and development purposes.
Manufacturing of radiolabeled peptides for pharmaceutical applications.
Production of generic peptides for biotech and research needs.
Custom synthesis of oligos for scientific and medical use.
People of PolyPeptide
Unlock access to complete
Unlock access to complete
Funding Insights of PolyPeptide
Detailed funding history for PolyPeptide
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PolyPeptide
Investment portfolio details for PolyPeptide
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PolyPeptide
Detailed financials for PolyPeptide
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Polypeptide Comparisons
Peer comparison for PolyPeptide
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PolyPeptide
PolyPeptide operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Ocelot Bio and Aperiam Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Company specializing in development of Biosimilars
|
|
| Locked | Locked | Locked |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| Locked | Locked | Locked |
CDMO and analytical services for peptide development are provided.
|
|
| Locked | Locked | Locked |
Ocelot Bio is a CDMO specializing in peptide manufacturing services.
|
|
| Locked | Locked | Locked |
Industrial and therapeutic proteins are manufactured by Aperiam Bio.
|
Detailed competitors of PolyPeptide
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Polypeptide
Complete news archive for PolyPeptide
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PolyPeptide
PolyPeptide was founded in 1952.
PolyPeptide is headquartered in Baar, Switzerland. It is registered at Baar, Zug, Switzerland.
Juan Jose Gonzalez is the current CEO of PolyPeptide.
As of Dec 31, 2024, the latest employee count at PolyPeptide is 1,360.
Annual revenue of PolyPeptide is $354.13M as on Dec 31, 2024.
PolyPeptide Labs is a CMO manufacturing proprietary (generally approved drug substances), GMP grade (for clinical trials) and non-GMP grade (small scale custom synthesis) - peptides for the pharmaceutical, cosmetic, biotechnology and veterinary markets. Using their synthetic technologies and methodologies, they manufacture peptides up to 80 amino acids in length and in quantities ranging from milligramgram to multi-10kg quantities. Depending on the nature and quantity of the peptide needed, a solid phase, a classical liquid phase, or a hybrid approach is developed for manufacturing. They claim to manufacture over one-third of all approved peptide drug substances (22 of 62 approved products worldwide) accounting for over 25 of the sales of outsourced peptide therapeutics worldwide.
PolyPeptide's top competitors include Enzene Biosciences, Hybio Pharmaceutical and AmbioPharm.
PolyPeptide offers Custom Research Grade Peptides, Radiolabeled Peptide, Generic Peptides, and Oligos.
Yes, PolyPeptide is publicly traded on SIX under the ticker symbol PPGN.
The ticker symbol of PolyPeptide is PPGN on SIX.